Ferry Ossendorp
Hoogleraar Moleculair gedefinieerde vaccinbiologie
- Naam
- Prof.dr. F.A. Ossendorp
- Telefoon
- +31 71 526 3800
- f.a.ossendorp@lumc.nl
- ORCID iD
- null
Ferry A. Ossendorp is hoogleraar Moleculaire Vaccinbiologie en hoofd van de Tumor Immunologie groep op de afdeling Immunologie van het Leids Universitair Medisch Centrum. Hij is ook lid van de Wetenschappelijke Raad van KWF Kankerbestrijding.
Moleculaire vaccin biologie en Tumor immunologie
Immuuntherapie heeft in de strijd tegen kanker een stevige plaats geworven naast de klassieke chemo- en radiatietherapieën. De waarneming dat het immuunsysteem ook maligne cellen kan aanvallen en de groei van kanker kan remmen is al lang bekend maar de cellulaire en moleculaire mechanismes zijn pas de laatste decaden duidelijk geworden. Moleculair ontwerp van kanker-specifieke vaccins met moderne kennis is een centraal onderzoeksthema. Therapeutische vaccinatie heeft als groot voordeel dat de geïnduceerde afweerreactie selectief tumoren aanvalt en de gezonde cellen onaangetast laat. In theorie dus de ideale therapie zonder heftige bijwerkingen. Het huidige onderzoek richt zich op beter begrip van de vaccinatie mechanismes en op mogelijkheden om het suppressieve milieu in de tumoren te beïnvloeden zodat immuuntherapie effectief kan werken. Hiertoe worden nieuwe combinatietherapieën in detail onderzocht.
Wetenschappelijke carrière
Ferry Ossendorp heeft Biologie gestudeerd op de Universiteit van Amsterdam en zijn promotieonderzoek gedaan aan het Nederlands Kanker Instituut in Amsterdam. Dit leidde tot promotie aan de Universiteit van Amsterdam. De titel van zijn proefschrift (1989) was: "Thyroid antigens and monoclonal antibodies in a thyroid tumor model". Vervolgens werd postdoc onderzoek gedaan aan de rol van T cel functies in kanker aan het Nederlands Kanker Instituut. Zijn carrière werd voortgezet als senior onderzoeker op een zelf verworven KWF project in het Academisch Ziekenhuis Leiden in 1993. Vanaf 1996 werd hij wetenschappelijk staflid op de afdeling Immunohematologie en Bloedtransfusie (nu Immunologie) op het Leids Universitair Medisch Centrum. In 2001 werd hij Universitair Docent en in 2005 Universitair Hoofddocent. Hij werd in November 2010 benoemd als hoogleraar Moleculair gedefinieerde Vaccinbiologie bij de faculteiten Geneeskunde en Wiskunde en Natuurwetenschappen. De titel van zijn oratie is: ”Op de juiste knopjes drukken”.
Al meer dan 25 jaar doet Ferry Ossendorp onderzoek naar het immuunsysteem en kanker en is nu hoofd van de Tumor Immunologie groep. Fundamenteel onderzoek naar het T cel immuunsysteem in verschillende facetten is centraal in zijn groep. Studies naar antigeen opname, processing en presentatie aan T cellen, de biologie van dendritische cellen en de regulatie van de immuniteit staan te doel om de afweerreacties tegen tumorcellen beter te begrijpen en immuuntherapie van kanker te verbeteren. Recent zijn onderzoeksresultaten uit het laboratorium en in proefdieren vertaalt in een vroege klinische studie waarin kankerpatienten worden ingespoten met een experimenteel tumor-specifiek peptide-conjugaat vaccin.
Prijzen en eervolle benoemingen
Ferry Ossendorp heeft persoonlijke subsidies verkregen bij NWO TOP (2011), CTMM (2011) en de Amerikaanse Cancer Research Institute CRI (2015). In 2016 werd de Leiden University Translational Drug Discovery & Development “Molecule to Man” Award verkregen met het doel patient-specifieke kanker immunotherapie te ontwikkelen.
Hoogleraar Moleculair gedefinieerde vaccinbiologie
- Faculteit Geneeskunde
- Divisie 4
- Immunologie
- IHB Tumorimmunologie
- Gu, Z.L.; Silva, C.G. da; Hao, Y.; Schomann, T.; Camps, M.G.M.; Maaden, K. van der; Liu, Q.; Ossendorp, F. & Cruz, L.J. (2023), Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer, Journal of Controlled Release 353: 490-506.
- Gu, Z.L.; Hao, Y.; Schomann, T.; Ossendorp, F.; Dijke, P. ten & Cruz, L.J. (2023), Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation, Journal of Controlled Release 357: 531-544.
- Chung, C.K.; Beekmann, U.; Kralisch, D.; Bierau, K.; Chan, A.; Ossendorp, F. & Cruz, L.J. (2022), Bacterial cellulose as drug delivery system for optimizing release of immune checkpoint blocking antibodies, Pharmaceutics 14(7).
- Pardieck, I.N.; Sluis, T.C. van der; Gracht, E.T.I. van der; Veerkamp, D.M.B.; Behr, F.M.; Duikeren, S. van; Beyrend, G.; Rip, J.; Nadafi, R.; Nejad, E.B.; Mulling, N.; Brasem, D.J.; Camps, M.G.M.; Myeni, S.K.; Bredenbeek, P.J.; Kikkert, M.; Kim, Y.; Cicin-Sain, L.; Abdelaal, T.; Gisbergen, K.P.J.M. van; Franken, K.L.M.C.; Drijfhout, J.W.; Melief, C.J.M.; Zondag, G.C.M.; Ossendorp, F. & Arens, R. (2022), A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection, Nature Communications 13(1).
- Hao, Y.; Chung, C.K.; Gu, Z.L.; Schomann, T.; Dong, X.X.; Veld, R.V.H. in 't; Camps, M.G.M.; Dijke, P. ten; Ossendorp, F.A. & Cruz, L.J. (2022), Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment, Molecular Biomedicine 3.
- Pardieck, I.N.; Duikeren, S. van; Veerkamp, D.M.B.; Brasem, D.J.; Redeker, A.; Bergen, J. van; Han, W.D.; Ossendorp, F.; Zondag, G. & Arens, R. (2022), Dominant antiviral CD8(+) T cell responses empower prophylactic antibody-eliciting vaccines against cytomegalovirus, Frontiers in Immunology 13.
- Hao, Y.; Chung, C.K.; Yu, Z.F.; Veld, R.H.I.V. 't; Ossendorp, F.A.; Dijke, P. ten & Cruz, L.J. (2022), Combinatorial therapeutic approaches with nanomaterial-based photodynamic cancer therapy, Pharmaceutics 14(1).
- Speetjens, F.M.; Welters, M.J.P.; Slingerland, M.; Poelgeest, M.I.E. van; Steenwijk, P.J.D. van; Roozen, I.; Boekestijn, S.; Loof, N.M.; Zom, G.G.; Valentijn, A.R.P.M.; Krebber, W.J.; Meeuwenoord, N.J.; Janssen, C.A.H.; Melief, C.J.M.; Marel, G.A. van der; Filippov, D.V.; Burg, S.H. van der; Gelderblom, H. & Ossendorp, F. (2022), Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions, Journal for ImmunoTherapy of Cancer 10(10).
- Hos, B.J.; Tondini, E.; Camps, M.G.M.; Rademaker, W.; Bulk, J. van den; Ruano, D.; Janssen, G.M.C.; Ru, A.H. de; Elsen, P.J. van den; Miranda, N.F.C.C. de; Veelen, P.A. van & Ossendorp, F. (2022), Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA, Cell Reports 41(2).
- Yu, Z.F.; Vepris, O.; Eich, C.; Feng, Y.S.; Que, I.; Camps, M.G.M.; Zhang, H.; Ossendorp, F.A. & Cruz, L.J. (2022), Upconversion nanoparticle platform for efficient dendritic cell antigen delivery and simultaneous tracking, Microchimica Acta 189(10).
- Arakelian, T.; Oosterhuis, K.; Tondini, E.; , M. los; Vree, J.; Geldorp, M. van; Camps, M.; Teunisse, B.; Zoutendijk, I.; Arens, R.; Zondag, G.; Ossendorp, F. & Bergen, J. van (2022), Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination, Vaccine 40(13): 2087-2098.
- in't Veld, R.V.H.; Lara, P.; Jager, M.J.; Koning, R.I.; Ossendorp, F. & Cruz, L.J. (2022), M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer, JOURNAL OF NANOBIOTECHNOLOGY 20(1).
- Tondini, E.; Reintjens, N.R.M.; Castello, G.; Arakelian, T.; Isendoorn, M.; Camps, M.; Vree, J.; Marel, G.A. van der; Filippov, D.V.; Codee, J.D.C. & Ossendorp, F. (2022), Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control, npj Vaccines 7(1).
- Ende T.C. van den, Heuts J.M.M., Gential G.P.P., Visser M., Graaff M.J. van de, Ho N.I., Jiskoot W., Valentijn A.R.P.M., Meeuwenoord N.J., Overkleeft H.S., Codée J.D.C., Burg S.H. van der, Verdegaal E.M.E., Marel G.A. van der, Ossendorp F. & Filippov D.V. (2021), Simplified monopalmitoyl toll-like receptor 2 ligand mini-UPam for self-adjuvanting neoantigen-based synthetic cancer vaccines, ChemBioChem 22(7): 1215-1222.
- Heuts J.M.M., Jiskoot W., Ossendorp F.A. & Maaden K. van der (2021), Cationic nanoparticle-based cancer vaccines, Pharmaceutics 13(5): 596.
- Speetjens F.M., Welters M.J.P., Slingerland M., Steenwijk P.D. van, Roozen I.C.F.M., Boekestijn S., Loof N., Zom G.G., Valentijn R., Krebber W.J., Melief C.J.M., Filippov D.V., Gelderblom H., Burg S.H. van & Ossendorp F.A. (2021), Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides, Journal of Clinical Oncology 39(15): 2614-2614.
- Lara, P.; Veld, R.V.H.I. 't; Jorquera-Cordero, C.; Chan, A.B.; Ossendorp, F. & Cruz, L.J. (2021), Zinc-phthalocyanine-loaded extracellular vesicles increase efficacy and selectivity of photodynamic therapy in co-culture and preclinical models of colon cancer, Pharmaceutics 13(10).
- Heuts, J.; Jiskoot, W.; Ossendorp, F. & Maaden, K. van der (2021), Cationic nanoparticle-based cancer vaccines, Pharmaceutics 13(5).
- Ho, N.I.; Camps, M.G.; Garcia-Vallejo, J.J.; Bos, E.; Koster, A.J.; Verdoes, M.; Kooyk, Y. van & Ossendorp, F. (2021), Distinct antigen uptake receptors route to the same storage compartments for cross-presentation in dendritic cells, Immunology 164(3).
- Veld, R.V.H.I. 't; Silva, C.G. da; Jager, M.J.; Cruz, L.J. & Ossendorp, F. (2021), Combining photodynamic therapy with immunostimulatory nanoparticles elicits effective anti-tumor immune responses in preclinical murine models, Pharmaceutics 13(9).
- Ho, N.I.; Camps, M.G.M.; Verdoes, M.; Munz, C. & Ossendorp, F. (2021), Autophagy regulates long-term cross-presentation by murine dendritic cells, European Journal of Immunology 51(4): 835-847.
- Fransen, M.F.; Hall, T. van & Ossendorp, F. (2021), Immune checkpoint therapy: tumor draining lymph nodes in the spotlights, International Journal of Molecular Sciences 22(17).
- Borst, J.; Busselaar, J.; Bosma, D.M.T. & Ossendorp, F. (2021), Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy, European Journal of Immunology 51(8).
- Leeuwen, T. van; Araman, C.; Pournara, L.P.; Kampstra, A.S.B.; Bakkum, T.; Marqvorsen, M.H.S.; Nascimento, C.R.; Groenewold, G.J.M.; Wulp, W. van der; Camps, M.G.M.; Janssen, G.M.C.; Veelen, P.A. van; Westen, G.J.P. van; Janssen, A.P.A.; Florea, B.I.; Overkleeft, H.S.; Ossendorp, F.A.; Toes, R.E.M. & Kasteren, S.I. van (2021), Bioorthogonal protein labelling enables the study of antigen processing of citrullinated and carbamylated auto-antigens, RSC Chemical Biology 2(3): 855-862.
- Reintjens N.R.M., Tondini E., Vis C., McGlinn T., Meeuwenoord N.J., Hogervorst T.P., Overkleeft H.S., Filippov D.V., Marel G.A. van der, Ossendorp F.A. & Codée J.D.C. (2020), Multivalent, stabilized mannose-6-phosphates for the targeted delivery of toll-like receptor ligands and peptide antigens, ChemBioChem 22(2): 434-440.
- Reintjens N.R.M., Tondini E., Jong A.R. de, Meeuwenoord N.J., Chiodo F., Peterse E., Overkleeft H.S., Filippov D.V., Marel G.A. van der, Ossendorp F.A. & Codée J.D.C. (2020), Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides, Journal of Medicinal Chemistry 63(20): 11691-11706.
- Reintjens, N.R.M.; Tondini, E.; Vis, C.; McGlinn, T.; Meeuwenoord, N.J.; Hogervorst, T.P.; Overkleeft, H.S.; Filippov, D.V.; Marel, G.A. van der; Ossendorp, F. & Codee, J.D.C. (2020), Multivalent, stabilized mannose-6-phosphates for the targeted delivery of toll-like receptor ligands and peptide antigens, ChemBioChem 22(2).
- Gu, Z.L.; Silva, C.G. da; Maaden, K. van der; Ossendorp, F. & Cruz, L.J. (2020), Liposome-based drug delivery systems in cancer immunotherapy, Pharmaceutics 12(11).
- Hernandez, I.B.; Yu, Y.X.; Ossendorp, F.; Korbelik, M. & Oliveira, S. (2020), Preclinical and clinical evidence of immune responses triggered in oncologic photodynamic therapy: clinical recommendations, Journal of Clinical Medicine 9(2).
- Chung, C.K.; Fransen, M.F.; Maaden, K. van der; Campos, Y.; Garcia-Couce, J.; Kralisch, D.; Chan, A.; Ossendorp, F. & Cruz, L.J. (2020), Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies, Journal of Controlled Release 323: 1-11.
- Ende, T.C. van den; Heuts, J.M.M.; Gential, G.P.P.; Visser, M.; Graaff, M.J. van de; Ho, N.I.; Jiskoot, W.; Valentijn, A.R.P.M.; Meeuwenoord, N.J.; Overkleeft, H.S.; Codee, J.D.C.; Burg, S.H. van der; Verdegaal, E.M.E.; Marel, G.A. van der; Ossendorp, F. & Filippov, D.V. (2020), Simplified monopalmitoyl toll-like receptor 2 ligand mini-U pam for self-adjuvanting neoantigen-based synthetic cancer vaccines, ChemBioChem 22(7).
- Reintjens, N.R.M.; Tondini, E.; Jong, A.R. de; Meeuwenoord, N.J.; Chiodo, F.; Peterse, E.; Overkleeft, H.S.; Filippov, D.V.; Marel, G.A. van der; Ossendorp, F. & Codee, J.D.C. (2020), Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides, Journal of Medicinal Chemistry 63(20): 11691-11706.
- in't Veld, R.V.H.; Ritsma, L.; Kleinovink, J.W.; Que, I.; Ossendorp, F. & Cruz, L.J. (2020), Photodynamic cancer therapy enhances accumulation of nanoparticles in tumor-associated myeloid cells, Journal of Controlled Release 320: 19-31.
- Chung, C.K.; Garcia-Couce, J.; Campos, Y.; Kralisch, D.; Bierau, K.; Chan, A.; Ossendorp, F. & Cruz, L.J. (2020), Doxorubicin loaded poloxamer thermosensitive hydrogels, Molecules 25(9).
- Sow, H.S.; Benonisson, H.; Brouwers, C.; Linssen, M.M.; Camps, M.; Breukel, C.; Claassens, J.; Hall, T. van; Ossendorp, F.; Fransen, M.F. & Verbeek, J.S. (2020), Immunogenicity of rat-neu(+) mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment, Scientific Reports 10(1).
- Mayoux, M.; Roller, A.; Pulko, V.; Sammicheli, S.; Chen, S.; Sum, E.; Jost, C.; Fransen, M.F.; Buser, R.B.; Kowanetz, M.; Rommel, K.; Matos, I.; Colombetti, S.; Belousov, A.; Karanikas, V.; Ossendorp, F.; Hegde, P.S.; Chen, D.S.; Umana, P.; Perro, M.; Klein, C. & Xu, W. (2020), Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy, Science Translational Medicine 12(534).
- Hos, B.J.; Camps, M.G.M.; Bulk, J. van den; Tondini, E.; Ende, T.C. van den; Ruano, D.; Franken, K.; Janssen, G.M.C.; Ru, A.; Filippov, D.V.; Arens, R.; Veelen, P.A. van; Miranda, N. & Ossendorp, F. (2020), Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer, OncoImmunology 9(1).
- Zom G.G., Willems M.M.J.H.P., Meeuwenoord N., Reintjens N.R.M., Tondini E., Khan S., Overkleeft H.S., Marel G.A. van der, Codée J.D.C., Ossendorp F. & Filippov D.V. (2019), Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells, Bioconjugate Chemistry 30(4): 1150-1161.
- Gential G.P.P., Hogervorst T.P., Tondini E., Graaff M.J. van de, Overkleeft H.S., Codée J.D.C., Marel G.A. van der, Ossendorp F. & Filippov D.V. (2019), Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7, Bioorganic and Medicinal Chemistry Letters 29(11): 1340-1344.
- Silva, C.G. da; Camps, M.G.M.; Li, T.M.W.Y.; Zerrillo, L.; Lowik, C.W.; Ossendorp, F. & Cruz, L.J. (2019), Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles, Theranostics 9(22): 6485-6500.
- Zom, G.G.; Willems, M.M.J.H.P.; Meeuwenoord, N.J.; Reintjens, N.R.M.; Tondini, E.; Khan, S.; Overkleeft, H.S.; Marel, G.A. van der; Codee, J.D.C.; Ossendorp, F. & Filippov, D.V. (2019), Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells, Bioconjugate Chemistry 30(4): 1150-1161.
- Sow, H.S.; Benonisson, H.; Breukel, C.; Visser, R.; Verhagen, O.J.H.M.; Bentlage, A.E.H.; Brouwers, C.; Claassens, J.W.C.; Linssen, M.M.; Camps, M.; Hall, T. van; Ossendorp, F.; Fransen, M.F.; Vidarsson, G. & Verbeek, J.S. (2019), Fc gamma R interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model, International Journal of Cancer 144(2): 345-354.
- Tondini, E.; Arakelian, T.; Oosterhuis, K.; Camps, M.; Duikeren, S. van; Han, W.D.; Arens, R.; Zondag, G.; Bergen, J. van & Ossendorp, F. (2019), A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control, OncoImmunology 8(11).
- Gential, G.P.P.; Hogervorst, T.P.; Tondini, E.; Graaff, M.J. van de; Overkleeft, H.S.; Codee, J.D.; Marel, G.A. van der; Ossendorp, F. & Filippov, D.V. (2019), Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7, Bioorganic and Medicinal Chemistry Letters 29(11): 1340-1344.
- Silva, C.G. da; Camps, M.G.M.; Li, T.M.W.Y.; Chan, A.B.; Ossendorp, F. & Cruz, L.J. (2019), Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines, Biomaterials 220.
- Verbeek J. S., Sow H. S., Benonisson H., Breukel C., Visser R., Verhagen O., Bentlage A., Brouwers C., Claassens J., Linssen M., Camps M., van Hall T., Ossendorp F., Herbert-Fransen M. & Vidarsson G. (2019), In anti-PD-L1 immunotherapy Fc gamma R interaction can add additional benefit depending on the tumor model, European Journal of Immunology 49: 1733-1734.
- Beyrend, G.; Gracht, E. van der; Yilmaz, A.; Duikeren, S. van; Camps, M.; Hollt, T.; Vilanova, A.; Unen, V. van; Koning, F.; Miranda, N.F.C.C. de; Arens, R. & Ossendorp, F. (2019), PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors, Journal for ImmunoTherapy of Cancer 7(1).
- Beyrend, G.; Stam, K.; Ossendorp, F. & Arens, R. (2019), Visualization and Quantification of High-Dimensional Cytometry Data using Cytofast and the Upstream Clustering Methods FlowSOM and Cytosplore, Journal of Visualized Experiments.
- Sow, H.S.; Benonisson, H.; Breukel, C.; Visser, R.; Verhagen, O.J.H.M.; Bentlage, A.E.H.; Brouwers, C.; Claassens, J.W.C.; Linssen, M.M.; Camps, M.; Hall, T. van; Ossendorp, F.; Fransen, M.F.; Vidarsson, G. & Verbeek, J.S. (2019), Fc gamma R interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model, International Journal of Cancer 144(2): 345-354.
- Kleinovink, J.W.; Mezzanotte, L.; Zambito, G.; Fransen, M.F.; Cruz, L.J.; Verbeek, J.S.; Chan, A.; Ossendorp, F. & Lowik, C. (2019), A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function, Frontiers in Immunology 9.
- Beyrend, G.; Gracht, E. van der; Yilmaz, A.; Duikeren, S. van; Camps, M.; Hollt, T.; Vilanova, A.; Unen, V. van; Koning, F.; Miranda, N.F.C.C. de; Arens, R. & Ossendorp, F. (2019), PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors, Journal for ImmunoTherapy of Cancer 7(1).
- Sow, H.S.; Ren, J.; Camps, M.; Ossendorp, F. & Dijke, P. ten (2019), Combined Inhibition of TGF- Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
- Kordalivand, N.; Tondini, E.; Lau, C.Y.J.; Vermonden, T.; Mastrobattista, E.; Hennink, W.E.; Ossendorp, F. & Nostrum, C.F. van (2019), Cationic synthetic long peptides-loaded nanogels: An efficient therapeutic vaccine formulation for induction of T-cell responses, Journal of Controlled Release 315: 114-125.
- Mangsbo S.M., Fletcher E.A.K., Maren W.W.C. van, Redeker A., Cordfunke R.A., Dillmann I., Dinkelaar J., Ouchaou K., Codee J.D.C., Marel G.A. van der, Hoogerhout P., Melief C.J.M., Ossendorp F. & Drijfhout J.W. (2018), Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses, Molecular Immunology 93: 115-124.
- Maaden K. van der, Heuts J.M.M., Camps M.G.M., Pontier M.J., Terwisscha van Scheltinga A., Jiskoot W., Ossendorp F.A. & Bouwstra J.A. (2018), Hollow microneedle-mediated micro-injections of a liposomal HPV E7(43-63) synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses, Journal of Controlled Release 269: 347-354.
- Hos B.J., Tondini E., Kasteren S.I. van & Ossendorp F.A. (2018), Approaches to Improve Chemically Defined Synthetic Peptide Vaccines, Frontiers in Immunology 9: 884.
- Fletcher E.A.K., Maren W. van, Cordfunke R., Dinkelaar J., Codee J.D.C., Marel G.A. van der, Melief C.J.M., Ossendorp F., Drijfhout J.W. & Mangsbo S.M. (2018), Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System, Journal of Immunology 201(1): 87-97.
- Zom G.G., Willems M.M.J.H.P., Khan S., Sluis T.C. van der, Kleinovink J.W., Camps M.G.M., Marel G.A. van der, Filippov D.V., Melief C.J.M. & Ossendorp F.A. (2018), Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication, Journal for ImmunoTherapy of Cancer 6(1): 146.
- Hos, B.J.; Tondini, E.; Kasteren, S.I. van & Ossendorp, F. (2018), Approaches to Improve Chemically Defined Synthetic Peptide Vaccines, Frontiers in Immunology 9.
- Maaden, K. van der; Heuts, J.; Camps, M.; Pontier, M.; Scheltinga, A.T. van; Jiskoot, W.; Ossendorp, F. & Bouwstra, J. (2018), Hollow microneedle-mediated micro-injections of a liposomal HPV E7(43-63) synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses, Journal of Controlled Release 269: 347-354.
- Mangsbo, S.M.; Fletcher, E.A.K.; Maren, W.W.C. van; Redeker, A.; Cordfunke, R.A.; Dillmann, I.; Dinkelaar, J.; Ouchaou, K.; Codee, J.D.C.; Marel, G.A. van der; Hoogerhout, P.; Melief, C.J.M.; Ossendorp, F. & Drijfhout, J.W. (2018), Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses, Molecular Immunology 93: 115-124.
- Fransen, M.F.; Benonisson, H.; Maren, W.W. van; Sow, H.S.; Breuke, C.; Linssen, M.M.; Claassens, J.W.C.; Brouwers, C.; Kaa, J. van der; Camps, M.; Kleinovink, J.W.; Vonk, K.K.; Heiningen, S. van; Klar, N.; Beek, L. van; Harmelen, V. van; Daxinger, L.; Nandakumar, K.S.; Holmdahl, R.; Coward, C.; Lin, Q.S.; Hirose, S.; Salvatori, D.; Hall, T. van; Kooten, C. van; Mastroeni, P.; Ossendorp, F. & Verbeekt, J.S. (2018), A Restricted Role for Fc gamma R in the Regulation of Adaptive Immunity, Journal of Immunology 200(8): 2615-2626.
- Chung, C.K.; Silva, C.G. da; Kralisch, D.; Chan, A.; Ossendorp, F. & Cruz, L.J. (2018), Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences, Journal of Controlled Release 285: 56-66.
- Hreinn Benonisson, Heng Sheng Sow, Cor Breukel, Jill WC Claassens, Conny Brouwers, Margot M Linssen, Anke Redeker, Marieke F Fransen, Thorbald van Hall, Ferry Ossendorp & Ramon Arens and JS Verbeek. (2018), FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines., Oncotarget 9(50).
- Hos, B.J.; Tondini, E.; Bulk, J. van den; Franken, C.L.M.C.; Janssen, G.M.C.; Veelen, P.A. van; Miranda, N.F. de & Ossendorp, F.A. (2018), Discovery of immunogenic neoantigens for peptide vaccination approaches in murine colorectal cancer.
- Heuts, J.; Varypataki, E.M.; Maaden, K. van der; Romeijn, S.; Drijfhout, J.W.; Scheltinga, A.T. van; Ossendorp, F. & Jiskoot, W. (2018), Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides, Pharmaceutical Research 35(11).
- Beyrend, G.; Stam, K.; Hollt, T.; Ossendorp, F. & Arens, R. (2018), Cytofast: A workflow for visual and quantitative analysis of flow andmass cytometry data to discover immune signatures and correlations, Computational and Structural Biotechnology Journal 16: 435-442.
- Gracht, A.M.F. van der; Geus, M.A.R. de; Camps, M.G.M.; Ruckwardt, T.J.; Sarris, A.J.C.; Bremmers, J.; Maurits, E.; Pawlak, J.B.; Posthoorn, M.M.; Bonger, K.M.; Filippov, D.V.; Overkleeft, H.S.; Robillard, M.S.; Ossendorp, F. & Kasteren, S.I. van (2018), Chemical Control over T-Cell Activation in Vivo Using Deprotection of trans-Cyclooctene-Modified Epitopes, ACS Chemical Biology 13(6): 1569-1576.
- Mayoux M., Roller A., Pulko V, Chen S., Fransen M., Kowanetz M., Rommel K., Matos I, Colombetti S., Belousov A., Karanikas V, Hegde P., Chen D., Mellman I, Umana P., Perro M., Ossendorp F., Klein C. & Xu W. (2018), Dendritic cells dictate the responsiveness to PD-L1 blockade in cancer, European Journal of Immunology 48: 22-23.
- Zom, G.G.; Willems, M.M.J.H.P.; Khan, S.; Sluis, T.C. van der; Kleinovink, J.W.; Camps, M.G.M.; Marel, G.A. van der; Filippov, D.V.; Melief, C.J.M. & Ossendorp, F. (2018), Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication, Journal for ImmunoTherapy of Cancer 6.
- Benonisson, H.; Sow, H.S.; Breukel, C.; Claassens, J.; Brouwers, C.; Linssen, M.M.; Fransen, M.F.; Sluijter, M.; Ossendorp, F.; Hall, T. van & Verbeek, J.S. (2018), High Fc gamma R Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy, Journal of Immunology 201(12): 3741-3749.
- Ho, N.I.; Camps, M.G.M.; Haas, E.F.E. de & Ossendorp, F. (2018), Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo, European Journal of Immunology 48(7): 1164-1173.
- Fransen, M.F.; Schoonderwoerd, M.; Knopf, P.; Camps, M.G.M.; Hawinkels, L.J.A.C.; Kneilling, M.; Hall, T. van & Ossendorp, F. (2018), Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy, JCI insight 3(23).
- Fletcher, E.A.K.; Maren, W. van; Cordfunke, R.; Dinkelaar, J.; Codee, J.D.C.; Marel, G. van der; Melief, C.J.M.; Ossendorp, F.; Drijfhout, J.W. & Mangsbo, S.M. (2018), Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System, Journal of Immunology 201(1): 87-97.
- Varypataki E.M., Benne N., Bouwstra J.A., Jiskoot W. & Ossendorp F.A. (2017), Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines, Cancer Immunology Research 5(3): 222-233.
- Silva, C.G. da; Peters, G.J.; Ossendorp, F. & Cruz, L.J. (2017), The potential of multi-compound nanoparticles to bypass drug resistance in cancer, Cancer Chemotherapy and Pharmacology 80(5): 881-894.
- Ho, N.I.; Camps, M.G.M.; Haas, E.F.E. de; Trouw, L.A.; Verbeek, J.S. & Ossendorp, F. (2017), C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes, Journal of Immunology 198(11): 4235-4243.
- Rad-Malekshahi, M.; Fransen, M.F.; Krawczyk, M.; Mansourian, M.; Bourajjaj, M.; Chen, J.; Ossendorp, F.; Hennink, W.E.; Mastrobattista, E. & Amidi, M. (2017), Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination, Molecular Pharmaceutics 14(5): 1482-1493.
- Kleinovink, J.W.; Fransen, M.F.; Lowik, C.W. & Ossendorp, F. (2017), Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8(+) T Cells, Cancer Immunology Research 5(10): 832-838.
- Kleinovink, J.W.; Hall, T. van; Ossendorp, F. & Fransen, M.F. (2017), PD-L1 immune suppression in cancer: Tumor cells or host cells?, OncoImmunology 6(7).
- Kleinovink, J.W.; Marijt, K.A.; Schoonderwoerd, M.J.A.; Hall, T. van; Ossendorp, F. & Fransen, M.F. (2017), PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy, OncoImmunology 6(4).
- Varypataki, E.M.; Benne, N.; Bouwstra, J.; Jiskoot, W. & Ossendorp, F. (2017), Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines, Cancer Immunology Research 5(3): 222-233.
- Doorduijn, E.M.; Sluijter, M.; Salvatori, D.C.; Silvestri, S.; Maas, S.; Arens, R.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2017), CD4(+) T Cell and NK Cell Interplay Key to Regression of MHC Class I-low Tumors upon TLR7/8 Agonist Therapy, Cancer Immunology Research 5(8): 642-653.
- Willems M.M.J.H.P., Zom G.G., Meeuwenoord N.J., Khan S., Ossendorp F.A., Overkleeft H.S., Marel G.A. van der, Filippov D.V. & Codée J.D.C. (2016), Lipophilic muramyl dipeptide-antigen conjugates as immunostimulating agents, ChemMedChem 11(2): 190-198.
- Silva A.L., Soema P.C., Slütter B., Ossendorp F. & Jiskoot W. (2016), PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity, Human Vaccines and Immunotherapeutics 12(4): 1056-1069.
- Pawlak J.B., Hos B.J., Graaff M.J. van de, Megantari O.A., Meeuwenoord N., Overkleeft H.S., Filippov D.V., Ossendorp F. & Kasteren S.I. van. (2016), The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes, ACS Chemical Biology : .
- Gential G.P., Ho N.I., Chiodo F., Meeuwenoord N., Ossendorp F., Overkleeft H.S., Marel G.A. van der & Filippov D.V. (2016), Synthesis and evaluation of fluorescent Pam3Cys peptide conjugates, Bioorganic and Medicinal Chemistry Letters 26(15): 3641-5.
- Zom G.G., Welters M.J., Loof N.M., Goedemans R., Lougheed S., Valentijn R.R., Zandvliet M.L., Meeuwenoord N.J., Melief C.J., Gruijl T.D. de, Marel G.A. van der, Filippov D.V., Ossendorp F. & Burg S.H. van der (2016), TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients, OncoTarget : .
- Varypataki E.M., Silva A.L., Barnier-Quer C., Collin N., Ossendorp F. & Jiskoot W. (2016), Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles, Journal of Controlled Release 226: 98-106.
- Pawlak, J.B.; Hos, B.J.; Graaff, M.J.V. de; Megantari, O.A.; Meeuwenoord, N.; Overkleeft, H.S.; Filippov, D.V.; Ossendorp, F. & Kasteren, S.I. van (2016), The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes, ACS Chemical Biology 11(11): 3172-3178.
- Pawlak, J.B.; Hos, B.; Megantari, O.A.; Ossendorp, F.A. & Kasteren, S.I. van (2016), Bias-free imaging of antigen degradation using bioorthogonal antigens, Journal of Immunology 196.
- Kleinovink, J.W.; Driel, P.B. van; Snoeks, T.J.; Prokopi, N.; Fransen, M.F.; Cruz, L.J.; Mezzanotte, L.; Chan, A.; Lowik, C.W. & Ossendorp, F. (2016), Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors, Clinical Cancer Research 22(6): 1459-1468.
- Silva, C.G. da; Rueda, F.; Lowik, C.W.; Ossendorp, F. & Cruz, L.J. (2016), Combinatorial prospects of nano-targeted chemoimmunotherapy, Biomaterials 83: 308-320.
- Streng-Ouwehand, I.; Ho, N.I.; Litjens, M.; Kalay, H.; Boks, M.A.; Cornelissen, L.A.M.; Singh, S.K.; Saeland, E.; Garcia-Vallejo, J.J.; Ossendorp, F.A.; Unger, W.W.J. & Kooyk, Y. van (2016), Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells, eLife 5.
- Willems, M.M.J.H.P.; Zom, G.G.; Meeuwenoord, N.; Khan, S.; Ossendorp, F.; Overkleeft, H.S.; Marel, G.A. van der; Filippov, D.V. & Codee, J.D.C. (2016), Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents, ChemMedChem 11(2): 190-198.
- Silva, A.L.; Soema, P.C.; Slutter, B.; Ossendorp, F. & Jiskoot, W. (2016), PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity, Human Vaccines and Immunotherapeutics 12(4): 1056-1069.
- Li, D.D.; Sun, F.L.; Bourajjaj, M.; Chen, Y.N.; Pieters, E.H.; Chen, J.; Dikkenberg, J.B. van den; Lou, B.; Camps, M.G.M.; Ossendorp, F.; Hennink, W.E.; Vermonden, T. & Nostrum, C.F. van (2016), Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds, Nanoscale 8(47): 19592-19604.
- Gential, G.P.P.; Ho, N.I.; Chiodo, F.; Meeuwenoord, N.; Ossendorp, F.; Overkleeft, H.S.; Marel, G.A. van der & Filippov, D.V. (2016), Synthesis and evaluation of fluorescent Pam(3)Cys peptide conjugates, Bioorganic and Medicinal Chemistry Letters 26(15): 3641-3645.
- Varypataki, E.M.; Silva, A.L.; Barnier-Quer, C.; Collin, N.; Ossendorp, F. & Jiskoot, W. (2016), Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles, Journal of Controlled Release 226: 98-106.
- Doorduijn, E.M.; Sluijter, M.; Querido, B.J.; Oliveira, C.C.; Achour, A.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2016), TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors, Journal of Clinical Investigation 126(2): 784-794.
- Zom, G.G.; Welters, M.J.P.; Loof, N.M.; Goedemans, R.; Lougheed, S.; Valentijn, R.R.P.M.; Zandvliet, M.L.; Meeuwenoord, N.J.; Melief, C.J.M.; Gruijl, T.D. de; Marel, G.A. van der; Filippov, D.V.; Ossendorp, F. & Burg, S.H. van der (2016), TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients, Oncotarget 7(41): 67087-67100.
- Burg, S.H. van der; Arens, R.; Ossendorp, F.; Hall, T. van & Melief, A.J.M. (2016), Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nature Reviews Cancer 16(4): 219-233.
- Silva A.L., Rosalia R.A., Varypataki E., Sibuea S., Ossendorp F. & Jiskoot W. (2015), Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation, Vaccine 33(7): 847-54.
- Rahimian S., Kleinovink J.W., Fransen M.F., Mezzanotte L., Gold H., Wisse P., Overkleeft H., Amidi M., Jiskoot W., Lowik C.W., Ossendorp F. & Hennink W.E. (2015), Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response, Biomaterials 37: 469-477.
- Varypataki E.M., Maaden K. van der, Bouwstra J.A., Ossendorp F.A. & Jiskoot W. (2015), Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity, AAPS Journal 17(1): 216-226.
- Pawlak J.B., Gential G.P.P., Ruckwardt T.J., Bremmers J.S., Meeuwenoord N.J., Ossendorp F.A., Overkleeft H.S., Filippov D.V. & Kasteren S.I. (2015), Bioorthogonal Deprotection on the Dendritic Cell Surface for Chemical Control of Antigen Cross-Presentation, Angewandte Chemie (International Edition) 54(19): 5628-5631.
- Rosalia R.A., Cruz L.J., Duikeren S. van, Tromp A.T., Silva A.L., Jiskoot W., Gruijl T. de, Löwik C., Oostendorp J., Burg S.H. van der & Ossendorp F.A. (2015), CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, Biomaterials 40: 88-97.
- Rahimian, S.; Kleinovink, J.W.; Fransen, M.F.; Mezzanotte, L.; Gold, H.; Wisse, P.; Overkleeft, H.; Amidi, M.; Jiskoot, W.; Lowik, C.W.; Ossendorp, F. & Hennink, W.E. (2015), Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response, Biomaterials 37: 469-477.
- Pawlak, J.B.; Gential, G.P.P.; Ruckwardt, T.J.; Bremmers, J.S.; Meeuwenoord, N.J.; Ossendorp, F.A.; Overkleeft, H.S.; Filippov, D.V. & Kasteren, S.I. van (2015), Bioorthogonal Deprotection on the Dendritic Cell Surface for Chemical Control of Antigen Cross-Presentation, Angewandte Chemie International Edition 54(19): 5628-5631.
- Sluis, T.C. van der; Duikeren, S. van; Huppelschoten, S.; Jordanova, E.S.; Nejad, E.B.; Sloots, A.; Boon, L.; Smit, V.T.H.B.M.; Welters, M.J.P.; Ossendorp, F.; Water, B. van de; Arens, R.; Burg, S.H. van der & Melief, C.J.M. (2015), Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death, Clinical Cancer Research 21(4): 781-794.
- Zehner, M.; Marschall, A.L.; Bos, E.; Schloetel, J.G.; Kreer, C.; Fehrenschild, D.; Limmer, A.; Ossendorp, F.; Lang, T.; Koster, A.J.; Dubel, S. & Burgdorf, S. (2015), The Translocon Protein Sec61 Mediates Antigen Transport from Endosomes in the Cytosol for Cross-Presentation to CD8(+) T Cells, Immunity 42(5): 850-863.
- Melief, C.J.M.; Hall, T. van; Arens, R.; Ossendorp, F. & Burg, S.H. van der (2015), Therapeutic cancer vaccines, Journal of Clinical Investigation 125(9): 3401-3412.
- Huber, S.K.R.; Camps, M.G.M.; Jacobi, R.H.J.; Mouthaan, J.; Dijken, H. van; Beek, J. van; Ossendorp, F. & Jonge, J. de (2015), Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.
- Li, D.D.; Kordalivand, N.; Fransen, M.F.; Ossendorp, F.; Raemdonck, K.; Vermonden, T.; Hennink, W.E. & Nostrum, C.F. van (2015), Reduction-Sensitive Dextran Nanogels Aimed for Intracellular Delivery of Antigens, Advanced Functional Materials 25(20): 2993-3003.
- Rahimian, S.; Fransen, M.F.; Kleinovink, J.W.; Christensen, J.R.; Amidi, M.; Hennink, W.E. & Ossendorp, F. (2015), Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation, Journal of Controlled Release 203: 16-22.
- Rahimian, S.; Fransen, M.F.; Kleinovink, J.W.; Amidi, M.; Ossendorp, F. & Hennink, W.E. (2015), Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer, Biomaterials 61: 33-40.
- Silva, A.L.; Rosalia, R.A.; Varypataki, E.; Sibuea, S.; Ossendorp, F. & Jiskoot, W. (2015), Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation, Vaccine 33(7): 847-854.
- Rahimian, S.; Fransen, M.F.; Kleinovink, J.W.; Amidi, M.; Ossendorp, F. & Hennink, W.E. (2015), Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer, Current Pharmaceutical Design 21(29): 4201-4216.
- Ho, N.I.; Camps, M.G.; Garcia-Vallejo, J.J.; Bos, E.; Kooyk, Y. van; Koster, A.J. & Ossendorp, F. (2015), Differential and sustained cross-presentation by DC subsets in vivo, Molecular Immunology 68(2): 147-147.
- Rosalia, R.A.; Cruz, L.J.; Duikeren, S. van; Tromp, A.T.; Silva, A.L.; Jiskoot, W.; Gruijl, T. de; Lowik, C.; Oostendorp, J.; Burg, S.H. van der & Ossendorp, F. (2015), CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, Biomaterials 40: 88-97.
- Varypataki, E.M.; Maaden, K. van der; Bouwstra, J.; Ossendorp, F. & Jiskoot, W. (2015), Cationic Liposomes Loaded with a Synthetic Long Peptide and Poly(I:C): a Defined Adjuvanted Vaccine for Induction of Antigen-Specific T Cell Cytotoxicity, AAPS Journal 17(1): 216-226.
- Zom G.G., Filippov D.V., Marel G.A. van der, Overkleeft H.S., Melief C.J. & Ossendorp F.A. (2014), Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule, OncoImmunology 3(7): e947892.
- Willems Marian M.J.H.P., Zom Gijs G., Khan Selina, Meeuwenoord Nico, Melief Cornelis J.M., Van der Stelt Mario, Overkleeft Herman S., Codee Jeroen D.C., Van der Marel Gijsbert A., Ossendorp Ferry & Filippov Dmitri V. (2014), N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-like Receptor 2, Journal of Medicinal Chemistry 57(15): 6873-6878.
- Willems M.M.J.H.P., Zom G.G., Meeuwenoord N., Ossendorp F.A., Overkleeft H.S., Van der Marel G.A., Codee J.D.C. & Filippov D.V. (2014), Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates, Beilstein Journal of Organic Chemistry 10: 1445-1453.
- Maaden K. van der, Varypataki E.M., Romeijn S.G., Ossendorp F.A., Jiskoot W. & Bouwstra J.A. (2014), Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice, European Journal of Pharmaceutics and Biopharmaceutics 88(2): 310-315.
- Zom Gijs G., Khan Selina, Britten Cedrik M., Sommandas Vinod, Camps Marcel G. M., Loof Nikki M., Budden Christina F., Meeuwenoord Nico J., Filippov Dmitri V., Van der Marel Gijsbert A., Overkleeft Hermen S., Melief Cornelis J.M. & Ossendorp Ferry (2014), Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates, Cancer Immunology Research 2(8): 756-764.
- Zom, G.G.; Filippov, D.V.; Marel, G.A. van der; Overkleeft, H.S.; Melief, C.J. & Ossendorp, F. (2014), Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule, OncoImmunology 3(7).
- Cruz, L.J.; Rosalia, R.A.; Kleinovink, J.W.; Rueda, F.; Lowik, C.W.G.M. & Ossendorp, F. (2014), Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: A comparative study, Journal of Controlled Release 192: 209-218.
- Maaden, K. van der; Varypataki, E.M.; Romeijn, S.; Ossendorp, F.; Jiskoot, W. & Bouwstra, J. (2014), Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice, European Journal of Pharmaceutics and Biopharmaceutics 88(2): 310-315.
- Willems, M.M.J.H.P.; Zom, G.G.; Khan, S.; Meeuwenoord, N.; Melief, C.J.M.; Stelt, M. van der; Overkleeft, H.S.; Codee, J.D.C.; Marel, G.A. van der; Ossendorp, F. & Filippov, D.V. (2014), N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-like Receptor 2, Journal of Medicinal Chemistry 57(15): 6873-6878.
- Quakkelaar, E.D.; Fransen, M.F.; Maren, W.W.C. van; Vaneman, J.; Loof, N.M.; Heiningen, S.H. van; Verbeek, J.S.; Ossendorp, F. & Melief, C.J.M. (2014), IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation, Journal of Immunology 192(12): 5813-5820.
- Boross, P.; Montfoort, N. van; Stapels, D.A.C.; Poel, C.E. van der; Bertens, C.; Meeldijk, J.; Jansen, J.H.M.; Verbeek, J.S.; Ossendorp, F.; Wubbolts, R. & Leusen, J.H.W. (2014), FcR gamma-Chain ITAM Signaling Is Critically Required for Cross-Presentation of Soluble Antibody-Antigen Complexes by Dendritic Cells, Journal of Immunology 193(11): 5506-5514.
- Rauen, J.; Kreer, C.; Paillard, A.; Duikeren, S. van; Benckhuijsen, W.E.; Camps, M.G.; Valentijn, A.R.P.M.; Ossendorp, F.; Drijfhout, J.W.; Arens, R. & Burgdorf, S. (2014), Enhanced Cross-Presentation and Improved CD8(+) T Cell Responses after Mannosylation of Synthetic Long Peptides in Mice, PLoS ONE 9(8).
- Zom, G.G.; Khan, S.; Britten, C.M.; Sommandas, V.; Camps, M.G.M.; Loof, N.M.; Budden, C.F.; Meeuwenoord, N.J.; Filippov, D.V.; Marel, G.A. van der; Overkleeft, H.S.; Melief, C.J.M. & Ossendorp, F. (2014), Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates, Cancer Immunology Research 2(8): 756-764.
- Fransen, M.F.; Cordfunke, R.A.; Sluijter, M.; Steenbergen, M.J. van; Drijfhout, J.W.; Ossendorp, F.; Hennink, W.E. & Melief, C.J.M. (2014), Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer, Vaccine 32(15): 1654-1660.
- Willems, M.M.J.H.P.; Zom, G.G.; Meeuwenoord, N.; Ossendorp, F.A.; Overkleeft, H.S.; Marel, G.A. van der; Codee, J.D.C. & Filippov, D.V. (2014), Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates, Beilstein Journal of Organic Chemistry 10: 1445-1453.
- Oliveira, C.C.; Sluijter, M.; Querido, B.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2014), Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire, Molecular Immunology 62(1): 129-136.
- Silva A.L., Rosalia R.A., Sazak A., Carstens M.G., Ossendorp F., Oostendorp J. & Jiskoot W. (2013), Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8(+) T cell activation, European Journal of Pharmaceutics and Biopharmaceutics 83(3): 338-345.
- Rosalia Rodney A., Silva Ana Luisa, Camps Marcel, Allam Ahmed, Jiskoot Wim, Van der Burg Sjoerd H., Ossendorp Ferry & Oostendorp Jaap (2013), Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles, Cancer Immunology, Immunotherapy 62(7): 1161-1173.
- Rosalia Rodney A., Quakkelaar Esther D., Redeker Anke, Khan Selina, Camps Marcel, Drijfhout Jan W., Silva Ana Luisa, Jiskoot Wim, Van Hall Thorbald, Van Veelen Peter A., Janssen George, Franken Kees, Cruz Luis J., Tromp Angelino, Oostendorp Jaap, Van derBurg Sjoerd H., Ossendorp Ferry & Melief Cornelis J.M. (2013), Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, European Journal of Immunology 43(10): 2554-2565.
- Fransen, M.F.; Sluis, T.C. van der; Ossendorp, F.; Arens, R. & Melief, C.J.M. (2013), Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8(+) T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects, Clinical Cancer Research 19(19): 5381-5389.
- Fransen, M.F.; Ossendorp, F.; Arens, R. & Melief, C.J.M. (2013), Local immunomodulation for cancer therapy Providing treatment where needed, OncoImmunology 2(11).
- Oliveira, C.C.; Querido, B.; Sluijter, M.; Groot, A.F. de; Zee, R. van der; Rabelink, M.J.W.E.; Hoeben, R.C.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2013), New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation, Journal of Immunology 191(8): 4020-4028.
- Rosalia, R.A.; Quakkelaar, E.D.; Redeker, A.; Khan, S.; Camps, M.; Drijfhout, J.W.; Silva, A.L.; Jiskoot, W.; Hall, T. van; Veelen, P.A. van; Janssen, G.; Franken, K.; Cruz, L.J.; Tromp, A.; Oostendorp, J.; derBurg, S.H. van; Ossendorp, F. & Melief, C.J.M. (2013), Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, European Journal of Immunology 43(10): 2554-2565.
- Arens, R.; Hall, T. van; Burg, S.H. van der; Ossendorp, F. & Melief, C.J.M. (2013), Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer, Seminars in Immunology 25(2): 182-190.
- Rosalia, R.A.; Silva, A.L.; Camps, M.; Allam, A.; Jiskoot, W.; Burg, S.H. van der; Ossendorp, F. & Oostendorp, J. (2013), Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles, Cancer Immunology, Immunotherapy 62(7): 1161-1173.
- Montfoort, N. van; Hoen, P.A.C. 't; Mangsbo, S.M.; Camps, M.G.M.; Boross, P.; Melief, C.J.M.; Ossendorp, F. & Verbeek, J.S. (2012), Fc gamma Receptor IIb Strongly Regulates Fc gamma Receptor-Facilitated T Cell Activation by Dendritic Cells, Journal of Immunology 189(1): 92-101.
- Duikeren, S. van; Fransen, M.F.; Redeker, A.; Wieles, B.; Platenburg, G.; Krebber, W.J.; Ossendorp, F.; Melief, C.J.M. & Arens, R. (2012), Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.
- Quakkelaar, E.D.; Rosalia, R.A.; Khan, S.; Oostendorp, J.; Burg, S.H. van der; Ossendorp, F. & Melief, C.J.M. (2012), Mechanism of superior cross-presentation of synthetic long peptides in comparison with protein for therapeutic cancer vaccination, Molecular Immunology 51(1): 25-25.
- Montfoort, N. van; Hoen, P.A.C. 't; Mangsbo, S.M.; Camps, M.G.M.; Boross, P.; Melief, C.J.M.; Ossendorp, F. & Verbeek, J.S. (2012), Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.
- Quakkelaar, E.D.; Rosalia, R.A.; Khan, S.; Oostendorp, J.; Burg, S.H. van der; Ossendorp, F. & Melief, C.J.M. (2012), Mechanism of superior cross-presentation of synthetic long peptides in comparison with protein for therapeutic cancer vaccination, Molecular Immunology 51(1): 38-38.
- Urban, S.; Textoris-Taube, K.; Reimann, B.; Janek, K.; Dannenberg, T.; Ebstein, F.; Seifert, C.; Zhao, F.; Kessler, J.H.; Halenius, A.; Henklein, P.; Paschke, J.; Cadel, S.; Bernhard, H.; Ossendorp, F.; Foulon, T.; Schadendorf, D.; Paschen, A. & Seifert, U. (2012), The Efficiency of Human Cytomegalovirus pp65(495-503) CD8(+) T Cell Epitope Generation Is Determined by the Balanced Activities of Cytosolic and Endoplasmic Reticulum-Resident Peptidases, Journal of Immunology 189(2): 529-538.
- Zom, G.G.P.; Khan, S.; Filippov, D.V.; Ossendorp, F. & Melief, C.J.M. (2012), TLR Ligand-Peptide Conjugate Vaccines: Toward Clinical Application, ADVANCES IN IMMUNOLOGY , VOL 114: SYNTHETIC VACCINES 114: 177-201.
- Silva, A.L.; Rosalia, R.A.; Sazak, A.; Carstens, M.G.; Ossendorp, F.; Oostendorp, J. & Jiskoot, W. (2012), Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8(+) T cell activation., European Journal of Pharmaceutics and Biopharmaceutics.
- Fransen, M.; Ossendorp, F.; Arens, R. & Melief, C.J.M. (2012), Controlled local delivery of CTLA-4 blocking antibody induces CD8+T cell dependent tumor eradication without systemic toxicity, Immunology 137: 708-708.
- Duikeren, S. van; Fransen, M.F.; Redeker, A.; Wieles, B.; Platenburg, G.; Krebber, W.J.; Ossendorp, F.; Melief, C.J.M. & Arens, R. (2012), Vaccine-Induced Effector-Memory CD8(+) T Cell Responses Predict Therapeutic Efficacy against Tumors, Journal of Immunology 189(7): 3397-3403.
- Roep, B.; Buckner, J.; Sawcer, S.; Toes, R. & Zipp, F. (2012), The problems and promises of research into human immunology and autoimmune disease, Nature Medicine 18(1): 48-53.
- Montfoort, N. van; Mangsbo, S.M.; Camps, M.G.M.; Maren, W.W.C. van; Verhaart, I.E.C.; Waisman, A.; Drijfhout, J.W.; Melief, C.J.M.; Verbeek, J.S. & Ossendorp, F. (2012), Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo, European Journal of Immunology 42(3): 598-606.
- Montfoort, N. van; Mangsbo, S.M.; Camps, M.G.M.; vanMaren, W.W.C.; Verhaart, I.E.C.; Waisman, A.; Drijfhout, J.W.; Melief, C.J.M.; Verbeek, J.S. & Ossendorp, F. (2012), Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo (vol 42, pg 598, 2012), European Journal of Immunology 42(6): 1648-1648.
- Zehner, M.; Rauen, J.; Chasan, A.I.; Embgenbroich, M.; Camps, M.G.; Kaden, S.; Haas, A.; Kurts, C.; Endl, E.; Beyer, M.; Grone, H.J.; Ossendorp, F. & Burgdorf, S. (2012), Intraendosomal flow cytometry: A novel approach to analyze the protein composition of antigen-loaded endosomes, European Journal of Immunology 42(8): 2187-2190.
- Unger, W.W.; Velthuis, J.; Abreu, J.R.F.; Laban, S.; Quinten, E.; Kester, M.G.D.; Reker-Hadrup, S.; Bakker, A.H.; Duinkerken, G.; Mulder, A.; Franken, K.L.M.C.; Hilbrands, R.; Keymeulen, B.; Peakman, M.; Ossendorp, F.; Drijfhout, J.W.; Schumacher, T.N. & Roep, B.O. (2011), Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers, Journal of Autoimmunity 37(3): 151-159.
- Boross, P.; Arandhara, V.L.; Martin-Ramirez, J.; Santiago-Raber, M.L.; Carlucci, F.; Flierman, R.; Kaa, J. van der; Breukel, C.; Claassens, J.W.C.; Camps, M.; Lubberts, E.; Salvatori, D.; Rastaldi, M.P.; Ossendorp, F.; Daha, M.R.; Cook, H.T.; Izui, S.; Botto, M. & Verbeek, J.S. (2011), The Inhibiting Fc Receptor for IgG, Fc gamma RIIB, Is a Modifier of Autoimmune Susceptibility, Journal of Immunology 187(3): 1304-1313.
- Unger, W.W.; Velthuis, J.; Abreu, J.R.F.; Laban, S.; Quinten, E.; Kester, M.G.D.; Reker-Hadrup, S.; Bakker, A.H.; Duinkerken, G.; Mulder, A.; Franken, K.L.M.C.; Hilbrands, R.; Keymeulen, B.; Peakman, M.; Ossendorp, F.; Drijfhout, J.W.; Schumacher, T.N. & Roep, B.O. (2011), Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers., Journal of Autoimmunity 37(3): 151-9.
- Boross, P.; Arandhara, V.L.; Martin-Ramirez, J.; Santiago-Raber, M.L.; Carlucci, F.; Flierman, R.; Kaa, J. van der; Breukel, C.; Claassens, J.W.C.; Camps, M.; Lubberts, E.; Salvatori, D.; Rastaldi, M.P.; Ossendorp, F.; Daha, M.R.; Cook, H.T.; Izui, S.; Botto, M. & Verbeek, J.S. (2011), The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility.
- Kessler, J.H.; Khan, S.; Seifert, U.; Gall, S. le; Chow, K.M.; Paschen, A.; Bres-Vloemans, S.A.; Ru, A. de; Montfoort, N. van; Franken, K.L.M.C.; Benckhuijsen, W.E.; Brooks, J.M.; Hall, T. van; Ray, K.; Mulder, A.; Doxiadis, I.I.N.; Swieten, P.F. van; Overkleeft, H.S.; Prat, A.; Tomkinson, B.; Neefjes, J.; Kloetzel, P.M.; Rodgers, D.W.; Hersh, L.B.; Drijfhout, J.W.; Veelen, P.A. van; Ossendorp, F. & Melief, C.J.M. (2011), Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes, Nature Immunology 12(1): 45U67.
- Quakkelaar, E.D.; Redeker, A.; Haddad, E.K.; Harari, A.; McCaughey, S.M.; Duhen, T.; Filali-Mouhim, A.; Goulet, J.P.; Loof, N.M.; Ossendorp, F.; Perdiguero, B.; Heinen, P.; Gomez, C.E.; Kibler, K.V.; Koelle, D.M.; Sekaly, R.P.; Sallusto, F.; Lanzavecchia, A.; Pantaleo, G.; Esteban, M.; Tartaglia, J.; Jacobs, B.L. & Melief, C.J.M. (2011), Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors, PLoS ONE 6(2).
- Carstens, M.G.; Camps, M.G.M.; Henriksen-Lacey, M.; Franken, K.; Ottenhoff, T.H.M.; Perrie, Y.; Bouwstra, J.A.; Ossendorp, F. & Jiskoot, W. (2011), Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines, Vaccine 29(29-30): 4761-4770.
- Carstens, M.G.; Maaden, K. van der; Velden, D. van der; Ottenhoff, T.H.M.; Melief, C.J.; Ossendorp, F.; Bouwstra, J.A. & Jiskoot, W. (2011), Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes, Journal of Liposome Research 21(4): 286-295.
- Carstens, M.G.; Maaden, K. van der; Velden, D. van der; Ottenhoff, T.H.M.; Melief, C.J.; Ossendorp, F.; Bouwstra, J.A. & Jiskoot, W. (2011), Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes., Journal of Liposome Research.
- Carstens, M.G.; Camps, M.G.M.; Henriksen-Lacey, M.; Franken, K.; Ottenhoff, T.H.M.; Perrie, Y.; Bouwstra, J.A.; Ossendorp, F. & Jiskoot, W. (2011), Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines., Vaccine 29(29-30): 4761-70.
- Florea, B.I.; Verdoes, M.; Li, N.; Linden, W.A. van der; Geurink, P.P.; Elst, H. van den; Hofmann, T.; Ru, A. de; Veelen, P.A. van; Tanaka, K.; Sasaki, K.; Murata, S.; Dulk, H. den; Brouwer, J.; Ossendorp, F.A.; Kisselev, A.F. & Overkleeft, H.S. (2010), Activity-Based Profiling Reveals Reactivity of the Murine Thymoproteasome-Specific Subunit beta 5t, Cell Chemistry Biology 17(8): 795-801.
- Hillaert W, Verdoes M, Florea BI, Saragliadis N, Habets KLL, Kuiper J, Van Calenbergh S, Ossendorp F, van der Marel GA & Driessen C (2009), Receptor-Mediated Targeting of Cathepsins in Professional Antigen Presenting Cells, Angewandte Chemie International Edition 48(9): 1629-1632.
- Fu N, Khan S, Quinten E, de Graaf N, Pemberton AJ, Rivett AJ, Melief CJM & Ossendorp F (2009), Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells, Vaccine 27(38): 5252-5258.
- Weterings JJ, Khan S, Drijfhout JW, Ossendorp F, Overkleeft HS, van der Marel GA & Filippov DV (2009), Synthesis of modified and hybrid protein derived biopolymers, Advances in Experimental Medicine and Biology 611: 141-142.
- Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester M, Chouquet A, Le Gorrec M, Drijfhout JW & Ossendorp F (2009), Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1(arg) NULL allele, Tissue Antigens 73(5): 387-387.
- Spierings E, Gras S, Reiser JB, Mommaas B, Ahnekinders M, Kester MGD, Chouquet A, Le Gorrec M, Drijfhout JW & Ossendorp F (2009), Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1(Arg) Null Allele, Journal of Immunology 182(8): 4809-4816.
- Han, W.G.H.; Schuurhuis, D.H.; Fu, N.; Camps, M.; Duivenvoorde, L.M. van; Louis-Plence, P.; Franken, K.L.M.C.; Huizinga, T.W.J.; Melief, C.J.M.; Toes, R.E.M. & Ossendorp, F. (2009), DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg, European Journal of Immunology 39(7): 1765-1773.
- Khan S, Weterings JJ, Britten CM, de Jong AR, Graafland D, Melief CJM, van der Burg SH, van der Marel G, Overkleeft HS, Filippov DV & Ossendorp F (2009), Chirality of TLR-2 ligand Pam(3)CysSK(4) in fully synthetic peptide conjugates critically influences the induction of specific CD8(+) T-cells, Molecular Immunology 46(6): 1084-1091.
- Weterings JJ, Khan S, van Noort GJV, Melief CJM, Overkleeft HS, van der Burg SH, Ossendorp F, van der Marel GA & Filippov DV (2009), 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation, Bioorganic and Medicinal Chemistry Letters 19(8): 2249-2251.
- van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, Griffith JM, Geuze HJ, van Hall T, Verbeek JS & Melief CJ (2009), Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity, Proceedings of the National Academy of Sciences 106(16): 6730-6735.
- Skowera A, Ellis RJ, Varela-Calvino R, Arif S, Huang GC, Van-Krinks C, Zaremba A, Rackham C, Allen JS, Tree TIM, Zhao M, Dayan CM, Sewell AK, Unger W, Drijfhout JW, Ossendorp F, Roep BO & Peakman M (2008), CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope, Journal of Clinical Investigation 118(10).
- Urban S, Textoris-Taube K, Reimann B, Kessler J, Paschen A, Ossendorp F, Foulon T, Schadendorf D, Kloetzel P & Seifert U (2008), Different role of cytosolic and ER-resident aminopeptidases in HCMVpp65 epitope generation, Wiener Klinische Wochenschrift 120.
- Spierings E, Gras S, Reiser J, Mommaas B, Almekinders M, Kester M, Chouquet A, Le Gorrec M, Drijfhout J, Ossendorp F, Housset D & Goulmy E (2008), Strong atomic HLA-peptide interactions explain the immunogenicity of the HA-1 minor H antigen, Tissue Antigens 72(3).
- Khan S, Bijker MS, Weterings JJ, Tanke HJ, Adema GJ, van Hall T, Drijfhout JW, Melief CJM, Overkleeft HS, van der Marel GA, Filippov DV, van der Burg SH & Ossendorp F (2007), Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells, Journal of Biological Chemistry 282(29).
- Montfoort, N. van; Jong, J.M.H. de; Schuurhuis, D.H.; Voort, E.I.H. van der; Camps, M.G.M.; Huizinga, T.W.J.; Kooten, C. van; Daha, M.R.; Verbeek, J.S.; Ossendorp, F. & Toes, R.E.M. (2007), A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+T lymphocytes, Journal of Immunology 178(12).
- Weterings JJ, Khan S, Kriek NMA, van der Marel GA, Overkleeft HS, Ossendorp F, van der Burg SH, Drijfhout JW & Filippov DV (2007), Synthesis of modified and hybrid protein derived biopolymers, Biopolymers 88(4).
- Unger WWJ, Pinkse GGM, Kracht SMVD, van der Slik AR, Kester MGD, Ossendorp F, Drijfhout JW, Serreze DV & Roep BO (2007), Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men., Annals of the New York Academy of Sciences 1103.
- de Jong JMH, Schuurhuis DH, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Ossendorp F, Toes REM & Verbeek JS (2006), Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8(+) T cells in vivo, Molecular Immunology 43(13).
- Schuurhuis DH, Fu N, Ossendorp F & Melief CJM (2006), Ins and outs of dendritic cells, International Archives of Allergy and Immunology 140(1).
- van Niel G, Wubbolts R, ten Broeke T, Buschow SI, Ossendorp FA, Melief CJ, Raposo G, van Balkom BW & Stoorvogel W (2006), Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination, Immunity 25(6).
- Schuurhuis, D.H.; Montfoort, N. van; Ioan-Facsinay, A.; Jiawan, R.; Camps, M.; Nouta, J.; Melief, C.J.M.; Verbeek, J.S. & Ossendorp, F. (2006), Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine, Journal of Immunology 176(8).
- de Jong JMH, Schuurhuis DH, Ioan-Facsinay A, Welling MM, Camps MGM, van der Voort EIH, Huizinga TWJ, Ossendorp F, Verbeek JS & Toes REM (2006), Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4(+) T cells upon immune-complex uptake in vivo, Immunology 119(4).
- Smyth LJC, Elkord E, Taher TEI, Jiang HR, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJM, Drijfhout JW, Dermime S, Hawkins RE & Stern PL (2006), CD8 T-cell recognition of human 5T4 oncofetal antigen, International Journal of Cancer 119(7).
- Weterings JJ, Khan S, van der Heden GJ, Drijfhout JW, Melief CJM, Overkleeft HS, van der Burg OH, Ossendorp F, van der Marel GA & Filippov DV (2006), Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines, Bioorganic and Medicinal Chemistry Letters 16(12).
- Hall, T. van; Wolpert, E.Z.; Veelen, P. van; Laban, S.; Veer, M. van der; Roseboom, M.; Bres, S.; Grufman, P.; Ru, A. de; Meiring, H.; Jong, A. de; Franken, K.; Teixeira, A.; Valentijn, R.; Drijfhout, J.W.; Koning, F.; Camps, M.; Ossendorp, F.; Karre, K.; Ljunggren, H.G.; Melief, C.J.M. & Offringa, R. (2006), Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants, Nature Medicine 12(4).
- Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJG, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F & Melief CJM (2006), BCR-ABL fusion regions as a source of multiple leukemia-specific CD8(+) T-cell epitopes, Leukemia 20(10).
- de Jong JMH, Schuurhuis DH, Ioan A, Van der Voort EIH, Huizinga TWJ, Ossendorp F, Verbeek JS & Toes REM (2005), Fc gamma R-mediated uptake and processing of antigen-immunoglobulin complexes by professional antigen presenting cells., Arthritis and Rheumatism 52(9).
- van Diepen A, van de Gevel JS, Koudijs MM, Ossendorp F, Beekhuizen H, Janssen R & van Dissel JT (2005), Gamma irradiation or CD4(+)-T-cell depletion causes reactivation of latent Salmonella enterica serovar Typhimurium infection in C3H/HeN mice, Infection and Immunity 73(5).
- Ossendorp F, Fu N, Camps M, Granucci F, Gobin SJP, van den Elsen PJ, Schuurhuis D, Adema GJ, Lipford GB, Chiba T, Sijts A, Kloetzel PM, Ricciardi-Castagnoli P & Melief CJM (2005), Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells, Journal of Immunology 174(12).
- Pinkse GGM, Tysma OHM, Bergen CAM, Kester MGD, Ossendorp F, van Veelen PA, Keymeulen B, Pipeleers D, Drijfhout JW & Roep BO (2005), Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes, Proceedings of the National Academy of Sciences 102(51).
- de Jong JMH, Schuurhuis DH, Ioan-Facsinay A, van der Voort EIH, Huzinga TJW, Ossendorp F, Verbeek JS & Toes REM (2005), Fc gamma R-mediated uptake and processing of antigen-immunoglobulin complexes by professional antigen-presenting cells, Arthritis Research and Therapy 7.
- van den Boogaardt DEM, van Hulst-van Miert PPMC, Koekkoek K, Melief KJM, Ossendorp F, Offringa R, Claas FHJ & Roelen DL (2005), Differentially modulated dendritic cells induce different types of regulatory T cells, Genes and Immunity 6.
- Kloetzel PM & Ossendorp F (2004), Proteasome and peptidase function in MHC-class-I-mediated antigen presentation.
- Roelen DL, van den Boogaardt DEM, van Miert PPMC, Koekkoek K, Melief CJM, Offringa R, Ossendorp F & Claas FHJ (2004), Specific modulation of the alloimmune response with alternatively activated dendritic cells, Genes and Immunity 5.
- Blok D, Feitsma HIJ, Kooy YMC, Welling MM, Ossendorp F, Vermeij P & Drijfhout JW (2004), New chelation strategy allows for quick and clean Tc-99m-labeling of synthetic peptides, Nuclear Medicine and Biology 31(6).
- Roelen DL, van den Boogaardt DEM, van Miert PPMC, Koekkoek K, Melief CJM, Offringa R, Ossendorp F & Claas FHJ (2003), Specific modulation of the alloimmune response with alternatively activated dendritic cells, Genes and Immunity 4.
- Spierings E, Brickner AG, Caldwell JA, Zegveld S, Tatsis N, Blokland E, Pool J, Pierce RA, Mollah S, Shabanowitz J, Eisenlohr LC, van Veelen P, Ossendorp F, Hunt DF, Goulmy E & Engelhard VH (2003), The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein, Blood 102(2).
- Roelen DL, Schuurhuis DH, Van Den Boogaardt DEM, Koekkoek K, Van Miert PPMC, Van Schip JJ, Laban S, Rea D, Melief CJM, Offringa R, Ossendorp F & Claas FHJ (2003), Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells, Transplantation 76(11).
- Mommaas B, Kamp J, Drijfhout JW, Beekman N, Ossendorp F, van Veelen P, den Haan J, Goulmy E & Mutis T (2002), Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus, Journal of Immunology 169(6).
- Schepers K, Toebes M, Sotthewes G, Vyth-Dreese FA, Dellemijn TAM, Melief CJM, Ossendorp F & Schumacher TNM (2002), Differential kinetics of antigen-specific CD4(+) and CD8(+) T cell responses in the regression of retrovirus-induced sarcomas, Journal of Immunology 169(6).
- Melief CJM, van der Burg SH, Toes REM, Ossendorp F & Offringa R (2002), Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes, Immunological Reviews 188.
- Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJM, Verbeek JS & Ossendorp F (2002), Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8(+) CTL responses in vivo, Journal of Immunology 168(5).
- Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJM, Taylor-Papadimitriou J & Offringa R (2002), Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope, Journal of Immunotherapy 25(1).
- Dolstra H, de Rijke B, Fredrix H, Balas A, Maas F, Scherpen F, Aviles MJ, Vicario JL, Beekman NJ, Ossendorp F, de Witte TM & van de Wiel-van Kemenade E (2002), Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes, European Journal of Immunology 32(10).
- Zwaveling, S.; Vierboom, M.P.M.; Mota, S.C.F.; Hendriks, J.A.; Ooms, M.E.; Sutmuller, R.P.M.; Franken, K.L.M.C.; Nijman, H.W.; Ossendorp, F.; Burg, S.H. van der; Offringa, R. & Melief, C.J.M. (2002), Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells, Cancer Research 62(21).
- Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, Laban S, Toes REM, Toebes M, Schumacher TNM, Bladergroen BA, Ossendorp F, Kummer JA, Melief CJM & Offringa R (2001), Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells, Journal of Experimental Medicine 194(5).
- Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DCJ, ten Bosch GJA, Kester MGD, Sijts A, Drijfhout JW, Ossendorp F, Offringa R & Melief CJM (2001), Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis, Journal of Experimental Medicine 193(1).
- Kleijmeer M, Ramm G, Schuurhuis D, Griffith J, Rescigno M, Ricciardi-Castagnoli P, Rudensky AY, Ossendorp F, Melief CJM, Stoorvogel W & Geuze HJ (2001), Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells, Journal of Cell Biology 155(1).
- Charo J, Geluk A, Sundback M, Mirzai B, Diehl AD, Malmberg KJ, Achour A, Huriguchi S, van Meijgaarden KE, Drijfhout JW, Beekman N, van Veelen P, Ossendorp F, Ottenhoff THM & Kiessling R (2001), The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65, European Journal of Immunology 31(12).
- Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M, Kloetzel PM, Neefjes JJ, Melief CJ & Ossendorp F (2000), Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site.
- Sijts AJAM, Standera S, Toes REM, Ruppert T, Beekman NJCM, van Veelen PA, Ossendorp FA, Melief CJM & Kloetzel PM (2000), MHC class I antigen processing of an Adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.
- Schuurhuis DH, Laban S, Toes REM, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EIH, Rea D, Offringa R, Geuze HJ, Melief CJM & Ossendorp F (2000), Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.
- Ossendorp F, Toes REM, Offringa R, van der Burg SH & Melief CJM (2000), Importance of CD4(+) T helper cell responses in tumor immunity, Immunology Letters 74(1).
- van Bergen J, Camps M, Offringa R, Melief CJM, Ossendorp F & Koning F (2000), Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide, Cancer Research 60(22).
- Offringa R, van der Burg SH, Ossendorp F, Toes REM & Melief CJM (2000), Design and evaluation of antigen-specific vaccination strategies against cancer, Current Opinion in Immunology 12(5).
- Melief CJM, Toes REM, Medema JP, Van der Burg SH, Ossendorp F & Offringa R (2000), Strategies for immunotherapy of cancer, Advances in Immunology 75.
- van Hall T, van Bergen J, van Veelen PA, Kraakman M, Henkamp LC, Koning F, Melief CJM, Ossendorp F & Offringa R (2000), Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin.
- van Hall T, Sijts A, Camps M, Offringa R, Melief C, Kloetzel PM & Ossendorp F (2000), Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28.
- van Bergen J, Ossendorp F, Jordens R, Mommaas AM, Drijfhout JW & Koning F (1999), Get into the groove! Targeting antigens to MHC class II.
- Adviseur
- Lid wetenschappelijke raad van KWF